Premium
Polymeric microparticle loaded with Atenolol as a drug delivery system to cardiovascular system
Author(s) -
Oliveira Naiara A,
Gomes Anderson J
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.580.6
Subject(s) - atenolol , zeta potential , drug , plga , drug delivery , microparticle , particle size , dynamic light scattering , materials science , pharmacology , biomedical engineering , chemistry , nanotechnology , chemical engineering , medicine , nanoparticle , blood pressure , engineering
This study aimed to investigate the effect of an established anti‐hypertensive drug such as atenolol (ATL) when encapsulated in polymeric microparticles (PLGA). ATL is a prominently drug on the cardioselective beta blockers list. It is a â1 blocker that has low lipid solubility. The new drug delivery system (ATL‐PLGA) was designed to protect the drug from environmental and to promote a sustained drug delivery profile. Parameters such as particle size, zeta potential, drug encapsulation efficiency, short‐term stability (at 37o ± 1 for 3 weeks) external morphology, and in vitro release behavior were evaluated at different preparation protocols. Scanning electron microscopy and dynamic light scattering revealed that particles loaded with ATL are spherical in shape, and they have a diameter between 92 and 512 nm and a low tendency to aggregate, with zeta potential −24.2 ± 3.4 mV. The encapsulation efficiency obtained in this procedure was 77.0± 4.6%. The particles are stable in the period of the study. The new drug delivery systems possess some features parameters that allow it to be tested in biological samples such as vascular smooth muscle cells. Supported by FAPDF, CAPES, CNPq, FINATEC and DPP‐UnB.